Pharmaceutical companies actively promote consistency evaluation, and recently a number of drugs have been evaluated

【Pharmaceutical Network Industry News】Through the consistency evaluation of generic drug quality and efficacy, it is conducive to enhancing the competitiveness of the product market, accumulating experience for the company's follow-up drug consistency evaluation work, and also conducive to exchanging price for quantity through collective procurement, so in recent years, pharmaceutical companies have been very active
in promoting consistency evaluation.
Data show that in October this year, CDE undertook a total of 218 acceptance numbers
for the consistency evaluation of generic drugs in the new registration classification.
Among them, 88 varieties have been evaluated, and Sichuan Kelun Pharmaceutical has gained more, winning a total of 3 drugs
.
In addition, in October, 15 varieties ushered in the first evaluation (including 3 first generic drugs), involving Yangtze River, Simcere Pharmaceutical, Xi'an Lijun Pharmaceutical and many other pharmaceutical companies.
.
.
At present, the time has come to November, and in just a few days, a number of drugs have been evaluated, involving flunarizine hydrochloride capsules of Harbin Pharmaceutical General Factory, Sinopharm modern dexamethasone sodium phosphate injection, etc
.
Harbin Pharmaceutical Co.
, Ltd.
On November 3, Harbin Pharmaceutical Co.
, Ltd.
announced that the branch Harbin Pharmaceutical General Factory recently received the "Drug Supplement Application Approval Notice" issued by the State Medical Products Administration on flunarizine hydrochloride capsules, and the drug passed the consistency evaluation
of the quality and efficacy of generic drugs.
This medicine is mainly used for the preventive treatment
of typical (with aura) or atypical (without aura) migraine.
Symptomatic treatment
of vertigo caused by vestibular dysfunction.
As of the announcement date, Harbin Pharmaceutical General Factory has invested about 10.
2183 million yuan
in research and development expenses for the consistency evaluation of the quality and efficacy of the generic drug.
Sinopharm Modern On November 3, Sinopharm Modern announced that the wholly-owned subsidiary drug dexamethasone sodium phosphate injection passed the consistency evaluation
of generic drugs.
It is understood that dexamethasone sodium phosphate injection is mainly used for allergic and autoimmune inflammatory diseases, mostly used in connective tissue diseases, active rheumatism, rheumatoid arthritis, lupus erythematosus, etc
.
It is worth mentioning that before this, Xianju Pharmaceutical also announced that it had recently received the "Drug Supplement Application Approval Notice" approved and issued by the State Food and Drug Administration on dexamethasone sodium phosphate injection, and passed the consistency evaluation
of the quality and efficacy of generic drugs.
Xinhua Pharmaceutical Shandong Xinhua Pharmaceutical announced that Shandong Zibo Xinda Pharmaceutical Co.
, Ltd.
(Xinda Pharmaceutical), a wholly-owned subsidiary of the company, recently received the "Drug Supplement Application Approval Notice" approved and issued by the State Medical Products Administration, and the product consistency evaluation application was approved
.
Suntec cefaclor granules received the "Drug Supplement Application Approval Notice" in November 2022, and through the consistency evaluation of the quality and efficacy of generic drugs, the industry believes that this will help further enhance the market competitiveness of the product and help the implementation of
the company's large research and development strategy.
Shanghai Pharmaceutical Shanghai Pharmaceutical announced on the evening of November 1 that Shanghai New Asia Pharmaceutical Minhang Co.
, Ltd.
and Changzhou Pharmaceutical Factory Co.
, Ltd.
, the company's holding subsidiaries, respectively received the "Drug Supplement Application Approval Notice" issued by the State Food and Drug Administration on azithromycin tablets and terazosin hydrochloride tablets, and the above drugs passed the consistency evaluation
of generic drugs.
It is reported that the drug varieties that pass the consistency evaluation will receive greater support in the fields of medical insurance payment and medical institution procurement
.
Therefore, azithromycin tablets and terazosin hydrochloride tablets through the consistency evaluation of generic drugs, which is conducive to expanding the market share of the above drugs, enhancing market competitiveness, and also accumulating valuable experience
for the company's follow-up products to carry out the consistency evaluation of generic drugs.
.
.
.
.
.
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.